TheStreet Ratings

10 Best Healthcare & Biotech ETFs for 2016 - TheStreet Ratings

Top-Rated ETFs

Top Healthcare/Biotech ETFs as of 2/28/17

Fund NameGet InfoOverall RatingRisk Grade
iShares US Medical Devices ETFIHIAB
iShares US Healthcare Providers ETFIHFB+B
ETFis BioShares Biotech ProductsBBPB+C+
Fidelity MSCI Health Care Index ETFFHLCBB
Health Care Select Sector SPDRXLVBB
Vanguard HealthCare Index ETFVHTBB-
iShares US Healthcare ETFIYHBB-
ETFis BioShares Biotech Clinical TrBBCC+C-
ProShares Ultra Health CareRXLC+C-
First Trust AMEX BiotechnologyFBTC+C+

Source: TSC Ratings

Access our ETF Research Center

TheStreet Ratings' model ranks the risk-adjusted returns on all ETFs on a monthly basis.

The 10 healthcare and biotech ETFs (listed above) are ranked highest by TheStreet Ratings' methodology.

Best ETFs for

ETF Investing Center

Healthcare & Biotech ETFs

TrumpCare hasn't hit healthcare stocks yet
3/20/17 3:51AM
Gottlieb is the preferred FDA Commissioner pick of the drug industry and healthcare investors.
3/10/17 2:22PM
The Republican-led House of Representatives has rolled out a new health insurance bill. How will it affect health care sector companies' bottom lines?
3/9/17 4:05PM
The Democrats aim to generate public opposition to repeal by offering amendments that highlight fears the GOP plan will result in more expensive insurance and fewer people with coverage.
3/8/17 12:39PM
Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.
3/7/17 12:38PM
House Republicans finally have released their first detailed attempt to repeal and replace the Affordable Care Act.
3/7/17 7:04AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
2/17/17 7:44AM
Pfizer's fourth-quarter results were negatively impacted by the strong U.S. dollar, but they were largely in-line outside of that. These ETFs may benefit if Pfizer shares continue to rise.
2/1/17 1:10PM
Stocks hit record highs this week, indicating that the postelection surge still has momentum. Bargains are hard to find, but this health giant is a smart value play now.
1/26/17 9:28AM